Aurora Cannabis Inc.

Aurora Cannabis Inc. (NASDAQ:ACB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ACB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-02, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for ACB spans 6-K, SC14D9F, 40-F.

Recent high-impact activity:

• Aurora Urges Shareholders to Reject Curaleaf's Hostile Bid, Citing $149M Cash vs $1B Debt (2026-09-02)
• Aurora Board Unanimously Rejects Curaleaf's Hostile Bid, Citing Inadequate Valuation and Regulatory Deficiencies (2026-09-02)
• Aurora Board Unanimously Rejects Curaleaf's $4.00 Hostile Bid, Citing Undervaluation and Debt Risks (2026-09-02)
• Aurora Rebuts Curaleaf's Hostile Bid Claims, Reveals UK Acquisitions and German Market Strength (2026-08-24)
• Aurora Cannabis Buys UK Distributor and Pharmacy for £2.1M (2026-08-19)

Insider Transactions

ACB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.